CytRx CEO Says Firm s RNAi Program is Buried, But Vows to Mine it for Value; Offers No Details | GenomeWeb

CytRx this week continued its migration away from the RNAi therapeutics space when President and CEO Steven Kriegsman said that the company's RNAi program is "buried" and has "no intrinsic value."

Kriegsman, speaking during his company's presentation at the Biotechnology Industry Organization CEO and Investor conference held in New York this week, also reaffirmed CytRx's plans to spin out the RNAi operations as a way to boost shareholder value — a challenge considering the company's balance sheet.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.